Alzheimer's disease stories

Aug 3, 2026

APOE2 gene protects brain from Alzheimer's by reducing DNA damage

Research shows the longevity-linked APOE2 gene protects brain cells by reducing DNA damage and helping neurons recover from stress, potentially opening new treatment paths for Alzheimer's disease.

Aug 3, 2026·1 source

May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source

Apr 23, 2026

Dopamine Loss Emerges as Key Driver of Memory Decline in Alzheimer’s

Study finds reduced dopamine signaling contributes to memory decline in Alzheimer’s, highlighting a previously underrecognized pathway and potential target for treatment.

Apr 23, 2026·3 sources

Top claims

▪The study's findings point toward new therapeutic strategies for Alzheimer's disease.
▪The Buck Institute study suggests APOE2 helps neurons avoid senescence, a damaged and poorly functioning cellular state common with age.
▪This finding suggests APOE2's protective effect may be transferable and not limited to individuals born with the gene variant.